| Literature DB >> 33886285 |
Skye R Doering1, Katie Freeman1, Ginamarie Debevec2, Phaedra Geer2, Radleigh G Santos3, Travis M Lavoi2, Marc A Giulianotti2, Clemencia Pinilla2, Jon R Appel2, Richard A Houghten2, Mark D Ericson1, Carrie Haskell-Luevano1.
Abstract
The central melanocortin-3 and melanocortin-4 receptors (MC3R, MC4R) are key regulators of body weight and energy homeostasis. Herein, the discovery and characterization of first-in-class small molecule melanocortin agonists with selectivity for the melanocortin-3 receptor over the melanocortin-4 receptor are reported. Identified via "unbiased" mixture-based high-throughput screening approaches, pharmacological evaluation of these pyrrolidine bis-cyclic guanidines resulted in nanomolar agonist activity at the melanocortin-3 receptor. The pharmacological profiles at the remaining melanocortin receptor subtypes tested indicated similar agonist potencies at both the melanocortin-1 and melanocortin-5 receptors and antagonist or micromolar agonist activities at the melanocortin-4 receptor. This group of small molecules represents a new area of chemical space for the melanocortin receptors with mixed receptor pharmacology profiles that may serve as novel lead compounds to modulate states of dysregulated energy balance.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33886285 PMCID: PMC8552302 DOI: 10.1021/acs.jmedchem.0c02041
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446